Taking ‘Achija’, the legacy of Indian fast-food to Toronto and New York – NewsPatrolling

Posted on December 7, 2020 by Prof Baldwin

When at Achija Youre Here, Youre Home stands justified as it has been a part of daily life for more than three decades to its clients and has held their utmost loyalty.

Achija is a chain of fast-food restaurants, established in the year 1987 in a Central Suburb of Mumbai by Lakhamshi Vershi Mange. Since their journey began, they have grown to eight successful restaurants spread across Mumbai & have also carved a strong foothold in the Indian fast-food segment, establishing themselves as solid partners for its management with renowned chains for 21 restaurants in Mumbai and Dubai & now are a legacy in itself.

Stepping into the hospitality industry in the year 2010 Tapan Mange (grandson of the founder), now a successful restaurateur & an entrepreneur started with Achijas first grandeur remote expansion. In the coming two years his execution and efforts gave a standardized business module to Achija, which for decades had practiced traditional business patterns. Mr. Mange then off his international exposure & experience in Dubai, created a vision to take the brand global.

Theres a great appreciation to the vegetarian franchises in an international market is a proven thing which now is even better known for good in today as the world is now preferring veganism or vegetarianism giving up or lowering on meat, which also aids in justifying your quality/flavour, to legitimize yourself & narrow down your competition as youre literally just competing off 100s being a vegetarian franchise than in 1000s like others then followed by a larger/loyal audience to be served. If youre passionate about serving the best and sustaining quality more than anything, your franchise would sure be gold & prime and would be admired anywhere in the world. Just be wise & loyal on your pick! is Tapan Manges mantra. With New York and Canada being the pick for Achija, he plans to take the legacy to the Big Apple, with a twist.

To give a further glimpse of the brand, its potential/positioning & its expansion Mr. Mange planning is to pilot Achijas new version of QSRs & Cloud Kitchens. Giving a new face to the Indian fast-food, Batata Vadas to its mouth-watering Bhaji in pocket bread, grilled potatoes with Bhaji, Pav-Bhaji Pizzas to a fun-filled wide array of Sandwiches & Rolls. Standards & Packaging to its best, handy & convenient to be consumed anytime & anywhere Aiming to serve Achijas best on/off-premises, Mr. Tapan mange while focusing on New Jersey, New York City and Toronto to cover it all within the first 12 months of its pilot launched. Sure good news for Gujaratis based in America.

Achija stands for its scrumptious Pav-Bhaji & its Mumbai Fast-Food diners step in for authentic Indian fast food while enjoys a kinder fusion of Modern Indo-western cuisine, pleasing palates across all ages. Their promise to taste and health has stayed true from the time it was established 30 years ago in a small joint to the eight self-owned outlets today. This shows it has the best potential from all perspectives be it the quality of its food, the utmost loyal decades-old customer base, its hygiene practices, or its traditional hospitality! Being a QSR it always has proven to be most efficiently managed and consistently been outstanding with regards to its market position, quality, customer satisfaction/loyalty with the limited available resources.

Over the last 30 years, Achija has successfully always been into top favorites amongst in the related localities and its competitions and so has been efficacious throughout and created a high & ever-growing loyal customer base. Also, it is highly recommended amongst Gujaratis which holds a strong presence in America, hence Achija is already being welcomed in the USA and Canada & goodwill held by the brand itself pre promises exposure to a colossal and loyal customer base.

Motivated by the success and growing demand for vegetarianism, Mr. Mange and his team have envisioned and embarked to set up a vegetarian legacy in the global market. Achija has always held an ever-growing Brand Loyal Customers who are frequent and enthusiastic visitors in Mumbai and its recalling and recognition would provide a firm base to Achija to cultivate the Brand Loyalty in the United States & Canada again which is the ultimate reward for successful marketers since Achijas customers are far less likely to be enticed to switch to other brands compared to non-loyal customers, says Tapan Mange, Entrepreneur- Restaurateur, Achija.

View post:
Taking 'Achija', the legacy of Indian fast-food to Toronto and New York - NewsPatrolling

I Went a Year Without Meat. Here’s What I Learned. – InsideHook

Posted on December 7, 2020 by Prof Baldwin

The closest I came was in Hawaii, all the way back in February. I was eating out with a big group of people Id just met, at a sushi restaurant on Oahus North Shore, sunburnt, drunk on sake, trading jokes that are better left out of print. A couple courses in, the waiter brought out a bamboo board with a lava rock grill, a plate with cooking fat, and a tray of marbled Hokkaido Wagyu steak. I audibly cursed.

Last November, I quit meat. Like everyone else, I havent caught up with too many people this year. But when I do, and that fresh fact eventually comes to light, they generally reply: Really? Why?

Ive found its easier to offer up a single, digestible reason indigestion, heart health, rain forests than tell the truth, which is that it was a long, incremental, incredibly dull process. One night I had snap peas and carrots with noodles instead of steak. I felt great on my run the next morning. A month later I watched a documentary about athletes and plant-based protein. A couple weeks after that I didnt order bacon on my Sunday morning egg sandwich. During a trip to a science museum in San Francisco, I learned about the link between cheeseburgers and deforestation. In the concluding chapter of one of my favorite non-fiction books I read last year, the author explained why hed moved on from meat. I read his words three times.

Eventually, there was a day that I had my last piece of meat. Thats how I know its been a year. But there was nothing ceremonial about it at the time. It became the last meal after the fact, after I decided that Id seen enough, that I could live without it, because apparently Id been trending in that direction for a long time.

Wagyu beef skewers, like the ones I passed up in Hawaii

Stefan Cristian Cioata/Getty Images

And then came Hawaii, where the waiter showed me how to spread the lard around the lava to get it ready for the beef. No one on the trip knew about my fledgling dietary decision. Even if they had, no one would have judged me for partaking. Still my mouth watering, my spirit shaky I held off. Instead, somewhat comically, I cooked a steak for a friend who was too far down the table to reach the station.

There are days that I miss it. I think about it a bit more around holidays, when its sizzling on the grill, or sitting there in the middle of the table, just the same as it always has. I ooh and aah with my roommate when we watch Parts Unknown, and Bourdain is in Uruguay or Oman and someone hands him a dripping, glistening piece of meat on a stick or over a bed of rice. (Ill ask myself, as if checking some sort of mental manual, whether it would be disrespectful to turn down a local delicacy if I were in the same situation.)

And I wonder, too, where Id be without the pandemic, which saved me a summer of having to smell hot dogs at Yankee Stadium. I like to sit in the left field bleachers, Section 237, where a couple dozen men start chanting CHI-CKEN BU-CKET! over and over again in the fifth inning. They proudly pick up their hollow tubs which not long before before housed 10 chicken tenders and a pound of fries then present them to a raucous crowd.

Its a testament to the growing diversity of plant-based personalities these days, I suppose, that I can write nostalgically about carnivorous days. Im not here to levy guilt, or link out to photos of animals kept in desolate conditions. I dont want to tell Americans to eat less meat. In fact, I dont need to. Recent surveys suggest that an overwhelming majority (90%) of Americans are eager to eat more fruits and vegetables, while a sizable figure (over 50%) are open to subbing out red meat for plant-based alternatives.

There are positives to this lifestyle choice enough that I have no plans to abandon it here at the start of year two but there are pitfalls, too, which I wish Id known more about before I started. However you come to your decision to divorce meat, either from months of diligent reading or after one bad bout with a burrito, you should know what to expect from the world youre entering into. So here are my takeaways from 12 months without beef, pork, poultry or fowl (I identified as a pescatarian, so I was still eating some seafood).

Maeda Rei/EyeEm

Giving up meat 30 years ago wasnt a bad idea. But it was bad timing. If your goal was to eat fewer animals, there were plenty of plants to choose from, but that was pretty much it. For years, our concept of diet was somewhat binary, hingeing on omnivores versus vegetarians, and a lack of creativity or optionality reflected this status quo. Thanks to the last half-decades revolution in plant-based products, though propelled by imitation meat giants based in Silicon Valley or the tech hubs of Europe going meatless doesnt have to mean only eating food grown in the ground or on trees. It also includes food grown in labs.

By 2027, the global plant-based food market will be worth $72.4 billion. Brands like Beyond Burger and Impossible Foods, which pioneered soy protein simulation meat, are now easily recognized and increasingly popular at grocery stores and fast-food joints across the country and world. A year ago, Id never had a plant-based burger in my life. This summer, I wrote an entire guide to grilling them. In fairness, not every vegetarian is interested in this new wave. But I certainly am: for me, the definitive arrival of alternative meats has lowered the intimidation barrier to a life without meat. Its eased the blow of removing all those familiar, beloved tastes from my life, as in their stead Ive come to truly enjoy and even crave certain plant-based foods.

An additional note on timing: the best is probably yet to come. In Tel Aviv, a company called SuperMeat recently became the worlds first to serve so-called cultured meat to a commercial public. They make a chicken sandwich sourcing the powers of cellular agriculture, harvesting meat without harming any animals. Its possible that 10 years from now we could all be accustomed to eating such cultured meat, which begs an interesting question. If you quit meat in 2020, why are you doing so? Would the promise of cruelty-free meat bring you back in 2030? Upon some internal reflection, I was interested to learn my answer is yes. That indicates to me that the treatment of animals and the preservation of the planet have become my biggest reasons for doing this.

Ive lost almost 20 pounds since I quit meat. Thats not necessarily weight I was trying to lose, but Ive also taken up long-distance running again, a sport which favors a lighter frame, so I dont mind. The running has definitely contributed to the weight loss. And yet its all interconnected, considering Ive run faster times (Im convinced of this) because I quit meat. The fitness aspect was a huge initial draw for me to a plant-based diet, and I can say, quite roundly, it has delivered. I was familiar with research at the outset. In theory, switching to a plant-based diet can trim your waistline, boost athletic performance, sharpen your day-to-day focus, increase your libido and improve your sleep. Those who eat a lot of red meat are at an increased risk of death from heart disease, stroke and diabetes. Vegetarians, by contrast, take in less calories and less fat.

I talked to one vegetarian at the start of this, who told me the most common question he gets is Where do you get your protein? Americans, especially American men, are extremely anxious about this concept, as if guzzling protein shakes is the silver bullet to fitness, instead of getting your heart rate up on a consistent basis. The reality is, I was getting way too much protein before I gave up meat, and I still take in more than enough. Most Americans consume double the amount that they need each day. A different question we might start asking ourselves is Where do you get your energy? I remember heading straight for the couch not the gym after eating particularly meaty dishes. Fatty, high-sodium foods close up the arterial pathways, making it difficult for blood vessels to oxygenate the body.

Thats not to say you cant get ripped on a diet of chicken and steak. Millions of people have. But it really just depends on your fitness goals. Ive moved away from bang-bang, short-run strength training in recent years in favor of running and functional, full-body fitness workouts. That brand of exercise requires more energy, better blood flow and an emptier stomach. Im in a great place these days. I recently ran my fastest mile in 10 years (4:43). Its important to remember, also, that a shift in focus from protein to energy could also have implications on longevity. Countless studies of metabolic health have linked a reduced protein-high carbohydrate diet to more years lived on the planet. This is true of every community with a disproportionate amount of centenarians (Blue Zones) throughout the world.

Im a big alternative meats guy, yes, but Ive also taken the plant part of the plant-based diet seriously this year. I have tried and tried cooking more foods this year, namely vegetables, than the previous five years combined. Its worth taking a break from meat just to remind yourself that as a food group, it can be a bit of a ball-hog. Meat is always looking for ways to dominate a meal. Theres a reason many men report feeling like a meal is incomplete or insufficiently filling without meat. But foods like cauliflower, Brussels sprouts and chickpeas can be a worthy main course if given a chance. During peak quarantine, my speciality became a tray of oven-roasted carrots dressed in honey, garlic and gorgonzola.

Photo by Ollie Millington/Getty Images

This is one of the pitfalls I mentioned earlier: there is a sense when you give up meat, that you have a ton of healthy credit in the bank. After all, youre constantly denying yourself a food group that is connected to bad heart health and a slew of other ailments. This must mean youve earned the right to fill up on anything flavorful that youre still allowed to eat, like pizza, potato chips and ice cream. When the main goal is to avoid meat, excessive consumption of butter, cheese and sugar feels reasonable, if even a little expected. But a full plant-based diet is only effective when meat is replaced with whole food alternatives; in fact, if a so-called junk food plant-based diet becomes your endgame, studies indicate that you would have been better off just sticking with meat.

To avoid rookie vegetarianism, prioritize real, whole foods. Think starchy vegetables, whole grains, healthy fats. Eschew processed foods with preservatives or thickeners. Earlier in the year, Id go to bed patting a stomach full of French fries and beer, thinking to myself Well done, still safe.Theres nothing wrong with consuming French fries and beer in moderation, at least but doing so to make up for a meatless lifestyle can be a slippery slope if youre not careful. The key for me has been keeping such simple pleasures sporadic and special. During the rest of the week, my diet trends boring. I like edamame, brown rice, pesto pasta. Peanut butter on an apple really gets me going.

In line with this philosophy, I should add, eating alternative meats every single night probably isnt a good idea. The reason theyre so tasty owes to the super-sized sodium levels. Look no further than their biggest partnerships (Burger King, Qdoba, Subway, KFC). Meatless meats dont carry the cancer risks of red meat, but theyre laden with empty caloriesand can pack four times as much salt as standard ground beef. Theyre also high in saturated fat. Youll get some nutritional value from the blends (black bean burgers have zinc and iron), but at the end of the day it should be considered a reminder of the old a comfort food, not an everyday choice. It carries the plant-based diet tag (really, a plant-based burger might as well be the movements mascot), but it has little to do with a more natural, whole-food plant-based diet.

Be prepared for the Spanish Inquisition: Why? How long have you been doing this? Is this who you are now? So what do you do if, like, youre at someone elses house for a BBQ? Doesnt plant-based meat have estrogen that makes men grow boobs? Do you think Im a monster for eating this burger right now? What kind of meat do you miss the most? Is it really that bad for the environment? Can you even build muscle anymore? Should I try it? Do you have to be an amazing cook? Does that actually taste like meat?

Just try to keep your cool. I truly do not mind fielding questions about a life without meat. Though occasionally misguided or misinformed, these questions are generally a sign of a populace in dietary flux, as millions of Americans have come to reconsider the impact their food choices have on their afternoon, their heart and the planet. Curiosity is a necessary, inevitable first step. In the last 12 months, two people I am quite close with also gave up meat. Others who I have lived with this year have made a conscious decision to eat less meat, as unofficial observers of the nations growing flexitarian movement.

Ive appreciated the solidarity, and I can only imagine what it was like for vegetarians decades ago, who had no Beyond or Impossible Burgers to tide their cravings. Ultimately, though, this is a personal choice, a decision made alone, one made again and again, every night, as I open the fridge and decide whats for dinner.

Whats my biggest takeaway after these 12 months? Its been a long year. Ive felt stomped-over, cramped, lost, confused and forgotten in 2020. But this decision, the reasons I did it and my resolve to stick with it even in the face of marbled Wagyu have all filled me with pride.

Subscribe herefor our free daily newsletter.

Originally posted here:
I Went a Year Without Meat. Here's What I Learned. - InsideHook

Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 – PharmiWeb.com

Posted on December 7, 2020 by Prof Baldwin

A new research document is added in DBMR database of 350 pages, titled as Global Cancer Nanomedicine Market Size, Share, Growth, Trends, Industry By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) Country and Forecast with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Alnylam Pharmaceuticals, Inc., Amgen Foundation, Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Cadila Pharmaceuticals, etc. The study conducted for Cancer Nanomedicine industry also analyses the market status, size, share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors with the help of SWOT analysis and Porters Five Forces Analysis.

Download Free Sample (350 Pages PDF, Full TOC, List of Tables & Figures, and Chart) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market

Data Bridge Market Research analyses the Cancer Nanomedicine Market to grow at a CAGR of 12.50% in the forecast period. The growing usages of nanomedicine in drug delivery technology will further create various opportunities for the growth of the market.

The Cancer Nanomedicine Market report encompasses the general idea of the global Cancer Nanomedicine market including definition, classifications, and applications. Further, it includes the all-inclusive comprehension of several factors such as drivers, constraints, and major micro markets. The report is a wide-ranging source of widespread facts and figures for business strategists as it offers the historical &futuristic data such as demand & supply data, cost, revenue, profit, supply chain value, and so on. Furthermore, it entails the key market features, comprising production, revenue, price, capacity, gross margin, market share, consumption, gross, production rate, demand/supply, cost, capacity utilization rate, export/import, and CAGR (compound annual growth rate). In addition the report encompasses global Cancer Nanomedicine market segmentation on the basis of diverse facets like product/service type, application, technology, end-users, and major geographic regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or insights of product sales, market share, and value along with the possible opportunities to grow or tap into in these regions.

Overview:

Surging volume of patients suffering from cancer, and other chronic disorders, increasing number of geriatric population across the globe, increasing development of nanotechnology-based drugs as well as therapies, adoption of advanced technologies are some of the factors which will likely to enhance the growth of the cancer nanomedicine market in the forecast period of 2020-2027. On the other hand, surging levels of investment on research and development activities along with introduction of advanced diagnostics procedure which will further bring immense opportunities for the growth of the cancer nanomedicine market in the above mentioned forecast period.

Low rate of adoption along with increasing side effects associated with the consumption of nanoparticles, stringent regulatory framework for approvals of drugs are acting as market restraints for the growth of the cancer nanomedicine market in the above mentioned forecast period.

According to this report Global Cancer Nanomedicine Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Cancer Nanomedicine Market includes comprehensive information derived from depth study on Cancer Nanomedicine Industry historical and forecast market data. Global Cancer Nanomedicine Market Size To Expand moderately as the new developments in Cancer Nanomedicine and Impact of COVID19 over the forecast period 2020 to 2027.

To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

Cancer Nanomedicine Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Cancer Nanomedicine Market report is helpful for strategists, marketers and senior management, And Key Players in Cancer Nanomedicine Industry.

Key Segmentation:

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

By Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems)

By Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others)

By Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI))

By Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III)

Leading Players operating in the Cancer Nanomedicine Market are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

The Cancer Nanomedicine market report also entails the vigorous evaluation about the growth plot and all opportunities &risk related to of global Cancer Nanomedicine market during the forecast period. In addition, the report comprises the key events and most recent innovations in the industry together with the prospective trends technological progresses within the global Cancer Nanomedicine market that can impact its expansion graph. Entailing the pivotal data on the markets statistics and dynamics, the report will serve as a valued asset in term of decision-making and guidance for the businesses and companies already active within industry or looking forward to enter into it.

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, cancer nanomedicine market is segmented into inorganic nanoparticles, and organic nanoparticles. Inorganic nanoparticles have been further segmented into synthesis of gold nanoparticle. Organic nanoparticles have been further segmented into polymeric nanoparticle, and lipid organic nanoparticles.

On the basis of agent type, cancer nanomedicine market is segmented into diagnostic agents, therapeutic agents, and drug delivery agents. Diagnostic agents have been further segmented into cancer biomarkers, diagnostic device and nanoprobes, and quantum dots. Diagnostic device and nanoprobes have been further sub segmented into biosensors, and microarrays. Therapeutic agents have been further segmented into photodynamic therapy, and photo thermal therapy.

Based on mechanism, cancer nanomedicine market is segmented into targeting tumor cells, nanocarrier drug complex, and drug release systems. Targeting tumor cells have been further segmented into passive targeting, and active targeting. Nanocarrier drug complex have been further segmented into liposomes, dendrimers, micelles, and inorganic nanocarriers.

On the basis of cancer type, cancer nanomedicine market is segmented into breast cancer, pancreatic cancer, brain cancer, lung cancer, and others.

Based on imaging technique, cancer nanomedicine market is segmented into positron emission tomography, single photon emitted tomography, and magnetic resonance imaging (MRI).

Cancer nanomedicine market has also been segmented based on the phase into research, preclinical, phase-I, phase-I/II, phase-II, and phase-III.

Geographically, the following regions together with the listed national/local markets are fully investigated:

For More Information or Query or Customization before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market

Reason to Buy

Access Full Report Directly @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cancer-nanomedicine-market

Also, Research Report Examines:

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Cancer Nanomedicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product

Competition by Company: Here, the competition in the Worldwide Cancer Nanomedicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Cancer Nanomedicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Cancer Nanomedicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Cancer Nanomedicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Cancer Nanomedicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Cancer Nanomedicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details @ https://www.databridgemarketresearch.com/reports/global-cancer-nanomedicine-market

Its vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Our Others Reports:

Online Testing Software Market Trends, Size, Growth Insight, Industry Share, Emerging Technologies by ProProfs, QuizWorks, ExamSoft, EDBASE, Testment

Health Surveillance Systems Market Size, Trends, Future Growth, Latest Technology, Innovation With Competitive Analysis by Top Players-Avigilon, Schneider Electric, Cisco, Tyco Integrated Security, Nedap N.V., ADT

Hyperhidrosis Treatment Market Size, Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by COVID-19 Impact Analysis 2027

Head Mirror Market Analysis with Top Trends, Size, Share, Leading Companies, Key Regions, Segments, Mergers and Foreseen By DBMR Till 2027

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

We provide a variety of services such as market verifiedindustry reports, technology trend analysis, Formative market research,strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475

Email corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Go here to read the rest:
Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 - PharmiWeb.com

Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing – Business Wire

Posted on December 7, 2020 by Prof Baldwin

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the start of its roadshow in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares (ADSs), each representing one ordinary share, in the United States (the U.S. Offering) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the European Offering and, together with the U.S. Offering, the Global Offering). The Company intends to grant the underwriters for the Global Offering (the Underwriters) a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

All securities to be sold in the Global Offering will be offered by the Company. The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol "NBTX." The Companys ordinary shares are listed on the regulated market of Euronext in Paris under the symbol "NANO."

Jefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Jefferies International Limited and Gilbert Dupont are acting as managers for the European Offering.

The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and ordinary shares sold in the Global Offering, will be determined following a bookbuilding process.

The ADSs and/or ordinary shares will be issued through a capital increase without shareholders preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1 of the French Monetary and Financial Code (Code montaire et financier) and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the 2nd and 7th resolutions of the Company's extraordinary general shareholders' meeting held on November 30, 2020.

The European Offering will be open only to qualified investors as such term is defined in article 2(e) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement on Form F-1 relating to the securities referred to herein has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement can be accessed by the public on the website of the SEC.

Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on the regulated market of Euronext in Paris pursuant to a listing prospectus subject to an approval from the French Autorit des marchs financiers (AMF) and comprising the 2019 Universal Registration Document (Document d'Enregistrement Universel) of the Company approved by the AMF on May 12, 2020 under number R. 20-010, as amended by its amendment filed with the AMF on November 20, 2020 under number D.20-0339-A01 and a Securities Note (Note dopration), including a summary of the prospectus. Copies of the 2019 Universal Registration Document and its amendment are available free of charge at the Companys head office located at 60, rue de Wattignies, 75012 Paris, France, on the Companys website (www.nanobiotix.com) and on the website of the AMF (www.amf-france.org).

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning the Global Offering as well as Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in its amendment filed with the AMF under number D.20-0339-A01 on November 20, 20 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

See the original post here:
Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing - Business Wire

Is the great stagnation over? – The Week

Posted on December 5, 2020 by Prof Baldwin

Shortly after the 1918 "Spanish Flu" departed, the Roaring Twenties arrived. History may not rhyme, but even an echo of that powerful economic boom would be most welcome.

Here's one reason why I'm cautiously hopeful that a kind of Roaring Twenties Redux might follow the coronavirus pandemic: Artificial intelligence researchers at Google's DeepMind unit announced Monday that an AI program had cracked the long-term problem of predicting how proteins in the human body fold into 3D shapes. "This long-sought breakthrough could accelerate the ability to understand diseases, develop new medicines and unlock mysteries of the human body," The New York Times reports.

Well, not just that as important as solving this 50-year riddle could turn out to be for human health and longevity. The possibly game-changing advance also suggests some legit reason for optimism that the apparent long-term slowdown in technological progress more broadly the "I was promised flying cars but got Twitter instead" syndrome might be ready to reverse. If that happens, get ready for faster economic growth and all the good things that go with it, such as higher wages. Or how about greater capacity to solve big problems that might not automatically show up in GDP numbers such as climate change and the threat of future pandemics?

To be sure, a long boom is not the current expectation from economists. Even the most bullish forecasts expect only a growth blip over the next couple of years as the economy rebounds from last spring's pandemic-induced shutdown. Maybe a boomy 2021 and 2022 before a deceleration back to the uninspiring 2 percent-ish pace we've been experiencing since the Global Financial Crisis of 2007-2009. The Congressional Budget Office recently predicted the economy's growth potential going forward will be almost a third slower than it has been over the past 50 years.

But AI could help change the gloomy forecast. Typically, the use case for AI is presented as automating operations such as customer service or improving decision-making through data analysis. And that stuff is important. Companies clearly think so, or they wouldn't be spending nearly $50 billion on AI systems this year. And the pandemic may be accelerating the trend. Moody's Analytics economist Mark Zandi said in a client note this week that many businesses "have taken advantage of the pandemic to more fully deploy technologies and process changes that they were investing in but reluctant to take full advantage of during the good times."

Maybe more important, however, is the role of AI as a super-researcher. In the paper "Are Ideas Getting Harder to Find?," economists Nicholas Bloom, Charles Jones, and John Van Reenen show how it's been getting harder to discover the big advances and breakthroughs that drive technological progress and economic growth. The low-hanging fruit have been picked. Their conclusion: "Just to sustain constant growth in GDP per person, the United States must double the amount of research effort every 13 years to offset the increased difficulty of finding new ideas."

But AI might go a long way toward solving this problem. Instead of thinking of AI as a general-purpose invention, some economists think of it as a general-purpose method of invention that can supercharge the research process. This protein-folding breakthrough is only the latest example. Back in February, MIT researchers announced they had discovered a new antibiotic using an AI approach similar to the one employed by DeepMind. "The computer model, which can screen more than a hundred million chemical compounds in a matter of days, is designed to pick out potential antibiotics that kill bacteria using different mechanisms than those of existing drugs," MIT's Anne Trafton reported. And in October, Wired magazine reported on InoBat, a Slovakia-based company using a U.S.-developed AI platform to analyze different lithium battery chemistries some 10 times faster than what was previously possible. This is only the beginning of the age of AI as the best-ever research assistant.

The 1918 influenza burned itself out. This time around, we are going to end a global pandemic ourselves through the application of technology specifically the light-speed development of vaccines. It probably won't be the last stunning innovation to transform our lives for the better this decade.

See the rest here:
Is the great stagnation over? - The Week

BioAge Raises $90M to Treat Aging and Age-related Diseases – GlobeNewswire

Posted on December 5, 2020 by Prof Baldwin

Proceeds will support advancement of the companys pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging

Company announces Chief Medical Officer as it prepares to enter clinic in 2021 with lead Phase 2-ready therapeutic compounds

RICHMOND, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial entrepreneur, Elad Gil, and included new investors Kaiser Foundation Hospitals, AARP Foundation (through the RockCreek Impact Fund) and Phi-X Capital, the fund of genomics entrepreneur Mostafa Ronaghi, among others. Current investors including Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures, and others also participated.

These additional funds will support advancement of our systems biology and data-driven platform to map the key pathways that drive human aging and our pipeline of medicines that target these pathways to reverse or eradicate diseases and extend healthspan, said Kristen Fortney, PhD, co-founder and chief executive officer. We look forward to advancing our first platform-derived therapies, BGE-117 and BGE-175 into clinical trials in the first half of 2021.

BioAge is at the forefront of understanding scientific drivers of aging with its unique and cutting-edge systems biology platform. We believe their approach has the potential to unlock the underlying pathologies of many diseases, such as Alzheimers, cardiovascular disease, and frailty, that disproportionately affect older populations, said Vijay Pande, PhD, general partner at Andreessen Horowitz.

Drugs that target aging have potential to treat several morbid diseases and improve the lives of older adults. BioAge has built a proprietary engine to analyze molecular signatures in aging populations, and to advance data-driven hypotheses to identify existing clinical-stage drugs that are ready for Phase 2 efficacy trials in age-related diseases. Im excited to work with them as they scale their platform and develop multiple therapies to improve the health of older individuals, said Elad Gil, PhD, entrepreneur and investor.

Proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increase healthspan and lifespan, augment BioAges artificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Separately, the company announced that Paul Rubin, M.D. will lead its clinical development efforts as chief medical officer. Dr. Rubin, a veteran biopharmaceutical drug developer, brings extensive experience from early discovery, late stage development and ultimate drug approvals across a wide variety of therapeutic areas in global geographies. In former roles heading development at Sepracor, GSK and Abbott, Dr. Rubin has been responsible for the clinical development and approval of more than ten products. Prior to BioAge, he was most recently executive vice president, Research and Development for MiRagen and held a similar role at Xoma, two biotechnology companies. Dr. Rubin earned his M.D. at Rush Medical College, Chicago.

Dr. Rubin commented, I am thrilled to be leading the BioAge clinical development team at this exciting time. Our platform provides a unique opportunity to identify targets relevant to the aging process and diseases associated with this process. Diseases common to older patients are often ignored despite their direct association with morbidity, mortality and decreased quality of life. The first two drugs from our pipeline are ready to begin Phase 2 trials in indications targeting serious conditions in elderly populations that presently have no good therapeutic options. A key aspect of our strategy is to initiate efficient human clinical trials that will demonstrate that our drugs can address age-related deficiencies in acute conditions, which may expedite approval and serve as a gateway to the treatment of chronic diseases, resulting in healthy aging.

About the BioAge Platform

The BioAge platform identifies key drug targets that will impact aging. The companys proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan and disease outcomes. BioAge has built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. BioAges pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

About BioAge

BioAge is a privately-held biotechnology company developing proprietary drugs to treat aging and aging- related diseases. Since its founding in 2015, the Company has raised $127 million in venture capital funding to back its AI-driven approach to map the molecular pathways that impact human longevity. BioAges mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the companys website at http://www.bioagelabs.com.

Source: BioAge Labs, Inc.

Contact Information:

BioAge | peng@bioagelabs.com

Media | swheeler@wheelhouselsa.com

Read more from the original source:
BioAge Raises $90M to Treat Aging and Age-related Diseases - GlobeNewswire

Tigerlily Foundation to Lead Historic Special Session on Health Equity, Collaboration and Partnership at the 2020 San Antonio Breast Cancer Virtual…

Posted on December 5, 2020 by Prof Baldwin

Tigerlily Foundation co-hosts this historic special session in collaboration with the American Association for Cancer Research (AACR), titled Setting the Stage for Health Equity, Collaboration and Partnership, on December 8, 2020, to discuss continued collaborative action towards health equity in breast cancer care, at SABCS 2020. The event is designed to foster transformational dialogue and lead to specific strategies to end barriers at every level of healthcare for people of color.

Washington, DC, December 05, 2020 --(PR.com)-- Tigerlily Foundation, a national breast cancer organization established by a Black, first-generation immigrant woman and patient-led organization will open the San Antonio Breast Cancer Symposium (SABCS). Maimah Karmo, President and Founder of the Tigerlily Foundation, has set the stage for a new day, as she has raised the bar higher in health equity, taking the stage as the first Black patient leader to co-host the opening special session at this global scientific conference. Although the path to representation and being on an equal playing field as scientists and researchers has been long, particularly as a woman of color, Karmo knew that the road to health equality and justice takes time; and in the midst of racial injustice, a global pandemic, and heightened disparities faced by people of color, the time was now to set and take the stage to usher in a new day.

Maimah Karmo and Dr. Chuck Perou, Professor of Genetics, LCCC Member, and Co-Director of the Computational Medicine Program at the University of North Carolina will co-host this session, with some of the most globally renowned scientists of color. Shawn Johnson, a medical student at Harvard Medical School will make a special presentation on the history of how racism, redlining, segregation, and institutional policies affects healthcare; followed by three presentations - by Dr. Lisa Newman surgical breast oncologist and Chief of the Section of Breast Surgery, and a physician scientist of Weill Cornell Medical College; Dr. Funmi Olopade, a breast medical oncologist and physician-scientist, and is a pioneer in cancer genetics, and the Walter L. Palmer Distinguished Service Professor of Medicine and Human Genetics and Director of the Center for Clinical Cancer Genetics and Global Health from the University of Chicago; and Dr. Maria Elena Martinez of UCSD, a Professor in the Herbert Wertheim School of Public Health and Human Longevity Science, who holds the Sam M. Walton Endowed Chair for Cancer Research and Co-leads Community Outreach & Engagement at the Moores Cancer Center.

This session builds on Tigerlily Foundations innovative and patient-first approach to engaging patients of color, and its historic Young Womens Metastatic Breast Cancer Disparities Fireside Chat, where Tigerlily Foundation brought the largest contingency of Black women to the conference, to host a conversation centered on understanding the gaps, misperceptions and barriers within the healthcare system that affect young women of color with metastatic breast cancer (MBC).

The 2020 SABCS special session will highlight this year's achievements Tigerlilys national MBC ANGEL Advocacy Training which educated women of color living with metastatic breast cancer and living in the 20 cities with the highest mortality rate of breast cancer; a COVID-19 Relief Program; a myriad of virtual on-line and COVID-safe in-personal activations in communities of color to provide education and access to screening; engagement of thousands of advocates nationwide; monthly bi-directional conversation series, between Black patient experts and non-Black healthcare professionals; and more than 400 million social media impressions from social and mainstream media focusing on health disparities, and directly impacting countless patients in local, national and global communities.

Most notably, Tigerlily Foundation launched the #inclusionpledge which provides a transparent and tangible framework across stakeholder sectors to identify and track equity actions, holding anyone accountable who through action or inaction impacts the lives of women of color to make specific and measurable change to improve outcomes for Black and Brown women.

For this Tigerlily Foundation and AACRs Special Session, Setting the Stage for Health Equity, Collaboration and Partnership, partners and attendees are invited to use their privilege for power by taking the #inclusionpledge.

At the 2019 SABCS, several advocates made an #inclusionpledge to only participate in advocacy initiatives panels, advisory boards, planning committees, programs - that include the experience of Black women. This year, the pledge has expanded and is a rallying cry and call to action, as Tigerlily Foundation encourages leaders in the breast cancer care ecosystem - pharmaceutical companies, clinical research organizations, clinicians, healthcare systems, healthcare payor systems and physician organizations and groups - to stand up and join those efforts with their own specific actions we can take now to help end disparities. Visit Tigerlily Foundation #InclusionPledge for Black Women to learn how you can collaborate on these efforts.

Race, literacy, financial barriers, access, social, systemic and hereditary backgrounds should not be determinants of life and health equity. To continue to accelerate impact as it relates to disparities and women of color, the #inclusionpledge is imperative. As an organization, Tigerlily Foundation was founded to address inequity of age, of stage and of color. We must see that health disparities is a racial justice and civil rights issue and work to end this injustice. Never again should there be health meetings without Black patients on the stage, providing real world input. There have been no ramifications for healthcare systems that has hurt when meant to heal, but one in which patients of color face unequal health treatment, limited access to clinical trials, unconscious bias and microaggressions - patients who the healthcare system has taken an oath to protect. This is the reality of living with cancer while being Black. If the global community could unite to develop three vaccines for COVID-19 in six months, eliminating all barriers to healthcare is possible. We can change this by enacting anti-racist policies across the globe and checks and balances to combat discrimination throughout every aspect of our healthcare system. We must have vulnerable, heart-based conversations, and healing on both sides. Being Black should not negate our right to live. The murder of George Floyd unveiled the inherent disregard for Black peoples lives. It is incumbent on all, especially those whose privilege allows for oppression of others, to use that privilege to end barriers. We launch the #inclusionpledge to advocate for and activate the inclusion of women of color across initiatives impacting their breast and overall health. Maimah Karmo, President, Tigerlily Foundation

This Special Session at the SABCS meeting is critically important and represents a step forward towards the goal of providing equitable health care to all. We are directly talking to the right audience, which represents thousands of cancer health care providers from around the world, and these are the people who can enact change. To accomplish this goal, we will discuss many of the possible causes of health care outcome disparities, be they societal or biological, and plan to identify solutions that will bring us closer to a level health care playing field. Charles M. Perou, PhD, The May Goldman Shaw Professor of Molecular Oncology

Im proud to be a part of this powerful session, where Tigerlily Foundation and the San Antonio Breast Cancer Symposium have partnered to create a landmark program of presentations highlighting the multi-factorial nature of breast cancer disparities. This session will feature groundbreaking research regarding the cascade of influences - ranging from socio-economics and systemic racism, to tumor biology and genetics - all of which converge to result in the 40% higher breast cancer mortality rates observed in African American compared to White American women. This session goes even further with groundbreaking discussion of how policy and advocacy can be leveraged to address and reverse these disparities, and the importance of true collaboration with patients as experts. Dr. Lisa Newman, Weill Cornell Medicine

The special session taking place at SABCS is important. Disparities in breast cancer care and survival outcomes for Black women have to be addressed now. It's time to shift the paradigm from limited narratives about socioeconomic status and poverty and bring attention to structural racism and provider bias that impacts the breast cancer care and survival of Black women. Jamil Rivers, Founder and CEO of The Chrysalis Initiative

This session will be aligned with a Twitter activation, which coincides with the graduation of his event is generously supported by AmGen, Athenex Oncology, Daiichi Sankyo, Immunomedics, Sanofi, SeaGen, Lily Oncology, Merck and Pfizer, and in partnership with the Iris Collaborative.

Event Information:Title: The SABCS Special Session - Presented by Tigerlily Foundation & AACRPoster Spotlight Sessions and Panel Discussions on Setting the Stage for Health Equity, Collaboration and Partnership (Panel Discussion, Twitter Chat and Facebook Live)Date/Time: December 8, 2020, 8:15a.m. 11:00 a.m. CSTLocation: Virtual Symposium, San Antonio, TexasRegister: https://www.sabcs.org/2020-SABCS-sup-sup/SABCS-sup-sup-Registration-VirtualContact: Email inclusionpledge@tigerlilyfoundation.org to interview participants at SABCS or in their local communities, or for more information on media, partnerships or sponsorship opportunities.

Contact Information:Tigerlily FoundationMamah Karmo888-580-6253Contact via Emailwww.tigerlilyfoundation.org

Read the full story here: https://www.pr.com/press-release/826753

Press Release Distributed by PR.com

Ciara and ex-Lululemon CEO launch new clothing brand with ‘more to it than fashion’ – CNBC

Posted on December 5, 2020 by Prof Baldwin

Grammy Award-winning artist Ciara has launched a new fashion company alongside her husband, NFL star Russell Wilson, and former Lululemon CEO Christine Day. But the brand, called the House of LR&C, has a mission beyond just the clothes it sells, Ciara and Day told CNBC on Wednesday.

"We're not only doing the fashion part. We're also combining the passion for fashion but also the passion for impact. That was really important to both Russell and I and also Christine in creating our company. There has to be more to it than fashion," Ciara said on "Closing Bell."

In addition to an emphasis on environmental sustainability, 3% of each purchase goes to the Why Not You Foundation, which Wilson founded in 2014. It supports efforts on education access, poverty reduction and children's health.

Day, who left Lululemon in late 2013 after more than five years at the athletic apparel company, said the launch of the brand during the coronavirus pandemic comes at an "inflection point" for the retail industry. "I think some of the things the consumers are looking for are really that sustainability, versatility, longevity in their garments," said Day, also a former executive at Starbucks.

She said the House of LR&C is looking to fill a gap in the market with younger shoppers who are socially minded. "They want to see companies building business models that matter, that have inclusion and unity and sustainability and love, and there's not enough of that in this world," Day said.

The company's two clothing lines for now are Good Man Brand, which Wilson founded in 2016, and the newly launched Human Nation, which sells casual, gender-neutral items. A women's brand also is in the works, Day said.

The official launch of the House of LR&C this week comes during the holiday shopping season, which has been altered by the pandemic. Monday was the largest U.S. internet shopping day ever, according to Adobe Analytics data.

Clothes are for sale directly through its website, but Day said going beyond the direct-to-consumer route by inking partnerships with Kohl's and Nordstrom also is critical. Ciara said the House of LR&C's mission was aligned with the retailers that are known for their brick-and-mortar presence.

"If you look at the landscape and just how the world is changing, especially with ... companies like Kohl's, they're also evolving with the times," Ciara said. "I've been fortunate to do some really cool things with Kohl's already. We just like where they were going with things. We sat down and talked about our vision for what we were doing, we really connected, and we felt that the plan they had really made sense for what we were trying to do and vice versa."

Here is the original post:
Ciara and ex-Lululemon CEO launch new clothing brand with 'more to it than fashion' - CNBC

Re-Inventing the Wheel: How CEOs Are Driving the Sustainable Tire of the Future – Triple Pundit

Posted on December 5, 2020 by Prof Baldwin

When the internal combustion engine is phased out and zero-emission electric vehicles rule the road, well still have tires. Lots of tires. After all, there is no substitute for the tire as we know it today and these everyday objects are more complex than you might think. Of course were all familiar with the outer tread made from synthetic and natural rubber, but tires also include other components made with a variety of materials, including steel, nylon, polyester and rayon.

The component-rich nature of tires serves to improve their longevity and performance. But their complexity makes it all the more important to understand the potential human health and environmental impacts associated with their lifecycle particularly as the number of vehicles on the road increases, topping the 1 billion mark for the first time in 2009. According to some estimates, this figure could hit 2 billion within 15 years.

With the potential for rising demand and corresponding impacts in mind, back in 2005 a group of leading tire company CEOs set out to study a range of tire lifecycle issues on an organized basis.

The idea gave birth to the Tire Industry Project. Organized as a voluntary collaboration under the umbrella of the World Business Council for Sustainable Development (WBCSD), the groups membership is currently comprised of 11 major tire companies and co-led by Bridgestone, Goodyear and Michelin.

With the assistance and work of independent consultants and advisors, TIP conducts original research and deploys analytic tools of its own invention. In addition to disseminating results to members, TIP shares information with government agencies, other research institutions and the general public.

TIP member companies account for more than 60 percent of the global tire industry. Through scheduled biennial meetings, participating CEOs select research topics based on potential human health and environmental impacts within the tire lifecycle. They also consider how TIP can fill existing knowledge gaps with original, scientific research.

The main role of TIP is to generate knowledge and science related to human health and environmental impacts, Director Anne Ccile Rmont told TriplePundit. TIP came from CEOs who realized that if they mutualized their efforts, it would be more efficient, and they would achieve a much greater impact.

TIP research bears that out. One of the initial projects involved identifying the most commonly used chemicals in tire manufacturing and assessing their current and potential regulatory status. The work resulted in a short list of chemicals that needed additional analysis.

In another early project, TIP discovered a void of science-based knowledge around the topic of particles generated by tires on the road. When TIP started its research, there was not even a science-based consensus on what the particles look like, how to collect samples, and how to evaluate them. The dearth of information on what are now known as tire and road wear particles (TRWP) led TIP to multiple research projects that continue to have significant impact on the research community, as attention turns to microplastics in the ocean and other emerging issues.

TIP started looking into understanding TRWP, how they are formed, what they look like, and what they are made of, in order to be able to recognize them and understand any potential impacts on human health and the environment, Rmont explained.

So far, the groups research indicates that TRWP are unlikely to negatively impact human health and the environment, and that few TRWP are likely to reach the ocean. But the project created a greater understanding of where the particles do settle before degradation namely, along roadsides and, to a lesser extent, in freshwater sediment, which could lead to a holistic approach to prevent TRWP from entering the environment.

From the initial focus on topics including the chemicals used in tire manufacturing, and tire wear, TIP has recently widened its scope to engage in broader sustainability issues tied to the tire industrys increasing use of natural rubber.

Natural rubber is, of course, biodegradable and renewable, but it comes with its own set of challenges. Natural rubber mainly comes from Southeast Asia, and 85 percent comes from smallholder farmers. Its production has been associated with a range of issues, including deforestation and [poor] working conditions, Rmont told TriplePundit.

In 2017, the CEOs of TIP agreed to support the formation of the Global Platform for Sustainable Natural Rubber (GPSNR), a multi-stakeholder organization focused on socioeconomic and environmental factors across the natural rubber value chain. We have been proactive in terms of looking for solutions, establishing an organization, creating benchmarks and performing a full lifecycle assessment, Rmont said.

In an update earlier this year, GPSNR outlined the scope of its mission, noting that the organization recognizes the need to work toward economic sustainability within the natural rubber industry, ensuring that the earnings of millions of smallholders and farmworkers are enough for them to enjoy a decent standard of living.

Further research into tire manufacturing chemicals and TRWP will continue this year and next. The coalition will also move stakeholder engagement around end-of-life tire management forward, having recently published an updated global state of knowledge report on the management of tires at end-of-life. And it will develop a World Business Council for Sustainable Development SDG Sector Roadmap, with the aim of articulating how the tire industry can work to support the U.N. Sustainable Development Goals.

In the coming months, in partnership with TIP, well take a closer look at each of these stages of the tire lifecycle, what the industry is doing to understand potential impacts, and how the sustainable tires of the future are taking shape. You can follow the series here.

This article series is sponsored by the Tire Industry Projectand produced by the TriplePundit editorial team.Members of the Tire Industry Project (in alphabetical order) are Bridgestone, Continental, Cooper Tire, Goodyear, Hankook, Kumho Tire, Michelin, Pirelli, Sumitomo Rubber, Toyo Tires, and Yokohama Rubber.

Image:Manuel Mena/Unsplash

View original post here:
Re-Inventing the Wheel: How CEOs Are Driving the Sustainable Tire of the Future - Triple Pundit

What is the secret to aging well? – MarketWatch

Posted on December 5, 2020 by Prof Baldwin

Heres the million, or lets say, billion-dollarquestion: What is aging well and how do you do it? Whats the secret elixir?

There are expert presentations on a TedTalk playlist: How toMake You Feel Good About Getting Older.And there are droves of self-help books, exercise regimes, healthy diet gurusand lines of cosmetics that this query has spawned.

Thats where Marc Freedman, founder and chief executive ofEncore.org and the author of How to Live Forever: The Enduring Power of Connecting the Generations, comes in.

Freedman is one of those experts on thelongevity revolution who makes you stop and listen. Really listen. Trust me onthis. In his latest book, out in paperback this week, he explores longevity,youth, purpose and happiness, and the role older people can play in giving backto the next generation.

Hes not a disciple of retirement. As he told me in an interview: All too often, individuals are left to their own devices when it comes to finding a new sense of purpose in a postretirement period that could be as long as the middle years in duration. Many feel like they are all alone in navigating the new terrain, practically and emotionally.

Learning to age well requires anemotional shift. More yesterdays than tomorrows has a way of adding an urgencyto this stage of life. Time is more precious. Freedman says. Questions ofpurpose and legacy are more prominent. That can sound depressing, but for manypeople it is a powerful source of motivation for making the most of thisperiod.

I spoke with Freedman about hisbook, How to Live Forever, and his views of aging well. The highlights of ourconversation are below and have been edited and condensed.

We now have more people over 60 in this country than under18. How can we make an aging society work?

America is becoming a much more multigenerational society,with five generations alive at the same time. This is no temporary blip; its apermanent shift. Some see this transformation producing a zero-sum battlebetween old and young over scarce resources, but this dystopian scenario runscounter to much of human history.

Actually, theres good reason for optimism. Anthropologists now believe it was the role of grandmothers caring for young children (and allowing mothers to gather more food) that served as the turning point in our becoming human beings in the first place. And developmental psychologists studying both ends of the age spectrum today are discovering that the needs and assets of younger and older people fit together like pieces of a jigsaw puzzle. Just ask any grandparent.

Nows the time to build on these inherent and complementaryassets. Lets find new ways to bring the generations together to forge bonds,find joint purpose, and bridge divides. Intergenerational connection could be adefining feature of American resilience in the 21st century.

How has the pandemic affected the generational divide?

Lets face it, a powerful message to our generation I saythis as a 62-year-old has been stay home, stay safe and stay out of theway. That message has reinforced ageism and the age segregation that has grownso rampant in American society. Its driven a wedge between generations, withinfamilies and in communities.

At the same time, by separating us, the pandemic hasawakened a deeper appreciation for our essential interdependence across age andled to calls for the creativity that will be needed to bring young and oldtogether again when its over.

You call for dramatic innovation in the ways we bringgenerations together. What are you seeing in the past few years that excitesyou?

Were going to need to be as creative in bringing people together across age as weve been in splitting them apart, an imperative all the more urgent in the context of COVIDs toll. The good news is that innovation is already under way.

I recounted many examples of innovative practices in Howto Live Forever, but Im even more heartened by the wave of innovation Ivewitnessed since the book was first published two years ago. One of my favoriteexamples is Nuns and Nones,originated by a group of young changemakers, spiritually-inclined butreligiously unaffiliated (the nones), who sought out older Women Religiousall over the country (the nuns) for guidance about living a good life andleaving the world better than we found it.

Nuns and Nones also underscores how much of the push towardgenerational connection and collaboration is coming from young people. Youngsocial entrepreneurs are behind Nesterly, a homesharingplatform that brings homeowners with room to spare together with collegestudents who need affordable rents; Big & Mini, acommunity thats reducing isolation by helping to create intergenerationalfriendships; and Mon Ami, an app thats beingused by governments and nonprofits to mobilize large-scale volunteer efforts.

And there are so many more. I encourage folks to take a lookat our 15 new Gen2Gen Innovation Fellows.The work theyre doing gives me confidence about our future.

How can individuals age-integrate their own lives, even inthe pandemic?

It all comes down to a pair of priorities: proximity andpurpose. Hows that for alliteration!

By proximity, I mean finding ways to encounter individuals of different ages and generations, whether in the course of daily life or even via Zoom. To resist the scourge of age segregation.And by purpose, Im talking about the need to make these intergenerational connections in ways that reinforce common, shared interests that animate our lives.

We could go a long way to finding proximity and purpose inthis country, for example, by creating intergenerational service programs aimedat connecting youngers and olders to use their complementary skills to solvelocal problems like contact tracing, feeding the hungry, educating children,and rebuilding after disasters.

But theres one more way to age-integrate that anyone can doright now, no infrastructure needed. In a word, listen. One of my mentors, inhis 80s at the time, once told me its a lot more important to be interestedthan to be interesting. Its certainly one of the keys to bridgingdifference, across age as well as many other divides.

Does it matter that we now have the oldest president in thenations history?

Its a striking paradox: Just as were pushing more and moreolder people to the sidelines during this time of pandemic increasing notonly loneliness but its close cousin, purposelessness weve also witnessedthe leadership of so many older men and women.

The nearly 80-year-old Dr. Anthony Fauci has served as a voice of calm reason and deep knowledge throughout the battle with COVID. Elder icons like the late Congressman John Lewis and Justice Ruth Bader Ginsburg continued their lifes work to build an equitable society with deep passion to the very end. And now we have the oldest president-elect in American history.

Some express legitimate concerns about a gerontocracy holding on to power at the expense of younger people. All the more reason that our elder leaders, starting with the new president, should take this moment to call the generations to common purpose, to ask old and young alike to roll up their sleeves to create a stronger, more cohesive society together, and to make the most of the multigenerational moment already washing over us.

Thanks for your time, Marc. My personal favorite takeaway. Its a lot more important to be interested than to be interesting.

Kerry Hannonisa leading expert and strategist on work and jobs, entrepreneurship, personalfinance and retirement. Kerry is the author of more than a dozen books,includingGreat Pajama Jobs: Your Complete Guide to Working From Home,Never Too Old To Get Rich: The Entrepreneurs Guide To Startinga Business Mid-Life,Great Jobs for Everyone 50+,andMoney Confidence.Her on Twitter@kerryhannon

Original post:
What is the secret to aging well? - MarketWatch

NUS-led team uncovers molecule that promotes muscle health when magnetised – Newswise

Posted on December 5, 2020 by Prof Baldwin

Newswise As people age, they progressively lose muscle mass and strength, and this can lead to frailty and other age-related diseases. As the causes for the decline remain largely unknown, promoting muscle health is an area of great research interest. A recent study led by the researchers from the National University of Singapore (NUS) has shown how a molecule found in muscles responds to weak magnetic fields to promote muscle health.

Led by Associate Professor Alfredo Franco-Obregn from the NUS Institute for Health Innovation and Technology (iHealthtech), the team found that a protein known as TRPC1 responds to weak oscillating magnetic fields. Such a response is normally activated when the body exercises. This responsiveness to magnets could be used to stimulate muscle recovery, which could improve the life quality for patients with impaired mobility, in an increasingly ageing society.

The use of pulsed magnetic fields to simulate some of the effects of exercise will greatly benefit patients with muscle injury, stroke, and frailty as a result of advanced age, said lead researcher Assoc Prof Franco-Obregn, who is also from the NUS Department of Surgery.

The NUS research team collaborated with the Swiss Federal Institute of Technology (ETH) on this study, and their results were first published online in Advanced Biosystems on 2 September 2020. The work was also featured on the cover of the journals print edition on 27 November 2020.

Magnets and muscle health

The magnetic fields that the research team used to stimulate the muscle health were only 10 to 15 times stronger than the Earths magnetic field, yet still much weaker than a common bar magnet, raising the intriguing possibility that weak magnetism is a stimulus that muscles naturally interact with.

To test this theory, the research team first used a special experimental setup to cancel the effect of all surrounding magnetic fields. The researchers found that the muscle cells indeed grew more slowly when shielded from all environmental magnetic fields. These observations strongly supported the notion that the Earths magnetic field naturally interacts with muscles to elicit biological responses.

To show the involvement of TRPC1 as an antenna for natural magnetism to promote muscle health, the researchers genetically engineered mutant muscle cells that were unresponsive to any magnetic field by deleting TRPC1 from their genomes. The researchers were then able to reinstate magnetic sensitivity by selectively delivering TRPC1 to these mutant muscle cells in small vesicles that fused with the mutant cells.

In their previous studies, the researchers have shown that response to such magnetic fields were strongly correlated to the presence of TRPC1, and it included the rejuvenation of cartilage by indirectly regulating the gut microbiome, fat burning and insulin-sensitivity via positive actions on muscle. The present study provided conclusive evidence that TRPC1 serves as an ubiquitous biological antenna to surrounding magnetic fields to modulate human physiology, particularly when targeted for muscle health.

Metabolic changes similar to those achieved with exercise have been observed in previous clinical trials and studies led by Assoc Prof Franco-Obregn. Encouraging benefits of using the magnetic fields to stimulate muscle cells have been found, with as little as 10 minutes of exposure per week. This tantalising possibility, to improve muscle health without exercising, could facilitate recovering and rehabilitation of patients with muscle dysfunction.

Assoc Prof Franco-Obregn shared, About 40 per cent of an average persons body is muscle. Our results demonstrate a metabolic interaction between muscle and magnetism which hopefully can be exploited to improve human health and longevity.

Next steps

This study represents a milestone in the understanding of how a key protein may developmentally react to magnetic fields.

Metabolic health such as weight, blood sugar levels, insulin, and cholesterol are strongly influenced by muscle health. As exercise is a strong modulator of metabolic diseases through the working of the muscles, and magnetic fields exert similar benefits of exercise, such magnetism may help patients who are unable to undertake exercise because of injury, disease, or frailty. As such, the NUS iHealthtech research team is now working to extend their study to reduce drug dependence for the treatment of diseases such as diabetes.

We hope that our research can help alleviate side effects by reducing the use of drugs for disease treatment, and to improve the quality of life of the patients, said Assoc Prof Franco-Obregn.

This project has recently won the Catalyst Award in the inaugural Healthy Longevity Catalyst Awards conferred by the US National Academy of Medicine. The team was recognised for their breakthrough innovation to extend human health and function later in life.

Read the original post:
NUS-led team uncovers molecule that promotes muscle health when magnetised - Newswise

Lifetime perspective on alcohol and brain health – The BMJ

Posted on December 5, 2020 by Prof Baldwin

Harm prevention policies must take the long view

The maintenance of brain health is central to health and wellbeing across the lifespan.1 Evidence suggests three periods of dynamic brain changes that may be particularly sensitive to the neurotoxic effects of alcohol: gestation (from conception to birth), later adolescence (15-19 years), and older adulthood (over 65 years). Highly prevalent patterns of alcohol use may cause harm during these sensitive periods, including low level prenatal alcohol exposure, adolescent binge drinking, and low-to-moderate alcohol use in older adulthood.2 Although these patterns of alcohol exposure may be associated with less harm to individuals than sustained heavy drinking, the overall burden of harm in populations is likely to be large.

From fetal development to later life, the human brain goes through several periods of dynamic change. The prenatal period is characterised by extensive production, migration, and differentiation of neurons, accompanied by substantial apoptosis.3 Adolescence is characterised by synaptic pruning and increased axonal myelination.4 Older adulthood is associated with brain atrophy, which accelerates after the age of 65 years, largely driven by decreases in neuron size and reductions in the number of dendritic spines and synapses.5 Each of these changes in neurocircuitry could increase sensitivity to the effects of environmental exposures such as alcohol.6

Globally, around 10% of pregnant women consume alcohol, with the rates considerably higher in European countries than the global average.7 Heavy alcohol use during pregnancy can cause fetal alcohol spectrum disorder, associated with widespread reductions in brain volume and cognitive impairment. But recent evidence indicates that even low or moderate alcohol consumption during pregnancy is significantly associated with poorer psychological and behavioural outcomes in offspring, partially mediated by aberrant brain structure.8

More than 20% of 15-19 year olds in European and other high income countries report at least occasional binge drinking (defined as 60 g of ethanol in a single drinking occasion).9 Longitudinal studies indicate that the transition to binge drinking in adolescence is associated with reduced neocortical volume and functional connectivity, attenuated white matter development, and small to moderate deficits in a wide range of cognitive functions.410 In older people, alcohol use disorders were recently shown to be one of the strongest modifiable risk factors for all types of dementia (particularly early onset) compared with other established risk factors such as hypertension and smoking.11

Although alcohol use disorders are relatively rare in older adults, many older people frequently consume low to moderate amounts of alcohol.12 Recently, even moderate drinking was shown to be associated with small but significant loss of brain volume in midlife,13 supporting previous research indicating an association between low risk drinking and brain damage in older adults.2 However, it is currently unclear whether these structural changes translate into functional cognitive impairment.

The evidence for the adverse effects of alcohol on brain health is compelling, but it is limited by the observational nature of the analyses. These findings require further replication, with a focus on more rigorous causal modelling.

Demographic trends may compound the effect of alcohol use on brain health. Women are now just as likely as men to drink alcohol and experience alcohol related harms.14 In higher income countries, consumption has increased among older people15 while in low and middle income countries, consumption and related harms have increased across the population. Global consumption is forecast to rise further in the next decade.16 The effects of the covid-19 pandemic on alcohol use and related harms are unclear, but alcohol use increased in the long term after other major public health crises.16

A lifecourse perspective on brain health supports the formulation of policy and public health interventions to reduce alcohol use and misuse at all ages. This could increase longevity and quality of life by reducing the prevalence of fetal alcohol spectrum disorders, aberrant neurocognitive development in adolescence, and dementia in later life. An integrated approach to harm reduction across the lifespan is required in public health, mental health, primary care, social care, and voluntary sectors.17

Population based interventions such as guidelines on low risk drinking, alcohol pricing policies, and lower drink driving limits need to be accompanied by the development of training and care pathways that consider the human brain at risk throughout life. The effect of harm reduction strategies on maintaining brain health in both individuals and populations can then be more fully evaluated.

Competing interests: We have read and understood BMJ policy on declaration of interests and have no interests to declare.

Provenance and peer review: Not commissioned; externally peer reviewed.

Read this article:
Lifetime perspective on alcohol and brain health - The BMJ

Stem Cell Market Analysis By Industry Value, Market Size, Top Companies And Growth Forecast To 2027 – Cheshire Media

Posted on December 5, 2020 by Prof Baldwin

Wilmington, November, 2020: Axiom Market Research & Consulting added a report on global Stem Cell which includes study on various market segments across various countries of key regions across the globe. Post COVID-19 pandemic impressive growth anticipated for this market. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the Stem Cell market.

Get Sample PDF Copy @ https://www.axiommrc.com/rqs/1661-stem-cell-market-report

Major Players in Stem Cell Market

Some of the key participants in the stem cells market include Cytori Therapeutics, Inc., Mesoblast Ltd., Astellas Pharma Inc., STEMCELL Technologies Inc., Osiris Therapeutics Inc, Celgene Corporation, BioTime, Inc., Cynata Therapeutics Limited, Human Longevity Inc, Cellular Engineering Technologies Inc., U.S. Stem Cell, Inc. BrainStorm Cell Therapeutics Inc. Caladrius Biosciences, Inc., and Promethera Biosciences.

Covid-19 Impact Analysis on Stem Cell Market

The global pandemic of Coronavirus (COVID-19) has triggered stock market unpredictability, tight border controls, and worldwide lockdown, leading the biotechnology industry, as well as large companies and governments, to restock supply chains. The whole world is experiencing severe impact on social and financial sectors, and all global industries are facing challenges during the COVID-19 pandemic. The exclusive COVID-19 Impact Analysis report by Axiom MRC explores the outbreak of COVID-19, its impact on the global and regional economies, and its implications on the healthcare sector. The report studies the effect of the pandemic on the global economy by evaluating factors like consumption, GDP, business investment, key players marketing strategies, key supply and demand-side factors, epidemiological swing factors, inventory, and governmental policies & decisions.

Stem Cell Market Segmental Highlights

Axiom has better understanding of various market segments due to its in-depth value chain analysis. Market size and forecast for the major market segments in terms of value and volume for the forecast period 2019 to 2027 presented in the report

Purchase This Report @ https://www.axiommrc.com/buy_now/1661-stem-cell-market-report

Stem Cell Market Regional Analysis

This study includes market size, share trend, competitive intelligence of developed markets, growth markets and niche regions/countries of:

Research objectives and key highlights of the market study:-

About us:

Axiom Market Research & Consulting is leading market research, business consulting and data analytics company serving the Fortune 5000 companies organizations of Healthcare, Chemicals, Food and Beverage, Technology etc. with quality solutions.

Call: USA +1(845)875-9786/UK +44(0)20 3286 9707/India +91 7020 342806

Email: [emailprotected]

Read this article:
Stem Cell Market Analysis By Industry Value, Market Size, Top Companies And Growth Forecast To 2027 - Cheshire Media

Go with the Flowbee: George Clooney reveals how he cuts his hair – The Guardian

Posted on December 5, 2020 by Prof Baldwin

With salons largely closed until this week, male grooming has been in freefall since the start of the spring lockdown. DIY haircuts have not been successful for all. Yet one Hollywood star has proved that even in a global pandemic, bad hair is not the great equaliser we hoped it would be.

George Clooney, the 59-year-old actor and human rights activist, has admitted to successfully cutting his own hair at home using a device called a Flowbee. My hairs really like straw, so its easy, he told CBS Sunday Morning.

According to Clooney, twice voted People magazines sexiest man alive, the $139.95 (103) contraption is so reliable he has been using it for more than 22 years and not simply during 2020. My haircuts take literally two minutes, he said, adding that its speed and efficiency had afforded him time to stain the garage doors, mop the floors and do much of the familys washing during lockdown in their Los Angeles home.

The Flowbee was a defining product of the 1980s infomercial boom in the US. It was designed in 1988 by Rick Hunts, a San Diego carpenter who was moved to invent the product after using his industrial vacuum cleaner to suck sawdust out of his hair. Hunts initially created and sold the gadget from his garage. But it was live demonstrations at a local county fair that edged him towards success, before global fame soon beckoned him, in the form of late-night TV demonstrations. By 2010, more than 2 million Americans had bought one.

In effect a pair of clippers with different length spacers and a suction tube, its longevity is partly down to theatrics according to various online tutorials, an up and down bouncing motion is best as well as positioning within popular culture. The Flowbee appeared in the cult 90s sitcoms Party of Five and Home Improvement, and was one of the many products parodied in the film Waynes World, where it was misnamed the suck cut. It helps too that the product is almost too ludicrous to forget.

Google searches for Flowbee took off following Clooneys weekend admission and the Flowbee website itself crashed. But while his endorsement will no doubt lend invaluable celebrity cachet to the brands image, largely unchanged since the 1980s, the Clooney effect is not in fact responsible for the products pandemic-era success.

As early as mid-March, the Flowbee had sold out on Walmarts website and on Amazon. It is not available in the UK and, according to Fortune magazine, Amazon says it doesnt know when the item will be back in stock. The UK saw a similar story when in April, John Lewis experienced a 200% increase in demand for clippers, and grooming tools from Philips and Remington sold out. All those products are, however, now available. According to its website, the Flowbee is not. Hunts, who demonstrates the model himself on the website, was not available for comment.

Visit link:
Go with the Flowbee: George Clooney reveals how he cuts his hair - The Guardian

Vaccines against COVID-19 will have side effects that’s a good thing – Kiowa County Press

Posted on December 5, 2020 by Prof Baldwin

A little bit of post-injection soreness is completely normal. Jose Luis Pelaez Inc/DigitalVision via Getty Images

Matthew Woodruff, Emory University

Takeaways

Temporary side effects from vaccines are a normal sign of a developing immune response.

Vaccines work by training your immune system to recognize and remember a pathogen in a safe way.

Expected side effects from a COVID-19 vaccine include redness and swelling at the injection site and stiffness and soreness in the muscle.

A potent vaccine may even cause fever. It does not mean that the vaccine gave you COVID-19.

In 2021 hundreds of millions of people will be vaccinated against SARS-CoV-2. The success of that COVID-19 vaccination campaign will heavily depend on public trust that the vaccines are not only effective, but also safe. To build that trust, the medical and scientific communities have a responsibility to engage in difficult discussions with the public about the significant fraction of people who will experience temporary side effects from these vaccines.

I am an immunologist who studies the fundamentals of immune responses to vaccination, so part of that responsibility falls on me.

Simply put, receiving these vaccines will likely make a whole lot of people feel crappy for a few days. That's probably a good thing, and it's a far better prospect than long-term illness or death.

In 1989, immunologist Charles Janeway published an article summarizing the state of the field of immunology. Until that point, immunologists had accepted that immune responses were initiated when encountering something foreign - bacteria, viruses, and parasites - that was "non-self."

Janeway suspected that there was more to the story, and famously laid out what he referred to as "the immunologist's dirty little secret": Your immune system doesn't just respond just to foreign things. It responds to foreign things that it perceives to be dangerous.

Now, 30 years later, immunologists know that your immune system uses a complex set of sensors to understand not only whether or not something is foreign, but also what kind of threat, if any, a microbe might pose. It can tell the difference between viruses - like SARS-CoV-2 - and parasites, like tapeworms, and activate specialized arms of your immune system to deal with those specific threats accordingly. It can even monitor the level of tissue damage caused by an invader, and ramp up your immune response to match.

Sensing the type of threat posed by a microbe, and the level of intensity of that threat, allows your immune system to select the right set of responses, wield them precisely, and avoid the very real danger of immune overreaction.

Vaccines work by introducing a safe version of a pathogen to a patient's immune system. Your immune system remembers its past encounters and responds more efficiently if it sees the same pathogen again. However, it generates memory only if the vaccine packs enough danger signals to kick off a solid immune response.

As a result, your immune system's need to sense danger before responding is at once extremely important (imagine if it started attacking the thousands of species of friendly bacteria in your gut!) and highly problematic. The requirement for danger means that your immune system is programmed not to respond unless a clear threat is identified. It also means that if I'm developing a vaccine, I have to convince your immune system that the vaccine itself is a threat worth taking seriously.

This can be accomplished in a number of ways. One is to inject a weakened - what immunologists call attenuated - or even killed version of a pathogen. This approach has the benefit of looking almost identical to the "real" pathogen, triggering many of the same danger signals and often resulting in strong, long-term immunity, as is seen in polio vaccination. It can also be risky - if you haven't weakened the pathogen enough and roll out the vaccine too fast, there is a possibility of unintentionally infecting a large number of vaccine recipients. In addition to this unacceptable human cost, the resulting loss of trust in vaccines could lead to additional suffering as fewer people take other, safer vaccines.

A safer approach is to use individual components of the pathogen, harmless by themselves but capable of training your immune system to recognize the real thing. However, these pieces of the pathogen don't often contain the danger signals necessary to stimulate a strong memory response. As a result, they need to be supplemented with synthetic danger signals, which immunologists refer to as "adjuvants."

To make vaccines more effective, whole labs have been dedicated to the testing and development of new adjuvants. All are designed with the same basic purpose - to kick the immune system into action in a way that maximizes the effectiveness and longevity of the response. In doing so, we maximize the number of people that will benefit from the vaccine and the length of time those people are protected.

To do this, we take advantage of the same sensors that your immune system uses to sense damage in an active infection. That means that while they will stimulate an effective immune response, they will do so by producing temporary inflammatory effects. At a cellular level, the vaccine triggers inflammation at the injection site. Blood vessels in the area become a little more "leaky" to help recruit immune cells into the muscle tissue, causing the area to become red and swell. All of this kicks off a full-blown immune response in a lymph node somewhere nearby that will play out over the course of weeks.

In terms of symptoms, this can result in redness and swelling at the injection site, stiffness and soreness in the muscle, tenderness and swelling of the local lymph nodes and, if the vaccine is potent enough, even fever (and that associated generally crappy feeling).

This is the balance of vaccine design - maximizing protection and benefits while minimizing their uncomfortable, but necessary, side effects. That's not to say that serious side effects don't occur - they do - but they are exceedingly rare. Two of the most discussed serious side effects, anaphalaxis (a severe allergic reaction) and Guillain-Barre Syndrome (nerve damage due to inflammation), occur at a frequency of less than 1 in 500,000 doses.

Side effects are normal.

Early data suggest that the mRNA vaccines in development against SARS-CoV-2 are highly effective - upwards of 90%. That means they are capable of stimulating robust immune responses, complete with sufficient danger signaling, in greater than nine out of 10 patients. That's a high number under any circumstances, and suggests that these vaccines are potent.

So let's be clear here. You should expect to feel sore at the injection site the day after you get vaccinated. You should expect some redness and swelling, and you might even expect to feel generally run down for a day or two post-vaccination. All of these things are normal, anticipated and even intended.

While the data aren't finalized, more than 2% of the Moderna vaccine recipients experienced what they categorized as severe temporary side effects such as fatigue and headache. The percentage of people who experience any side effects will be higher. These are signs that the vaccine is doing what it was designed to do - train your immune system to respond against something it might otherwise ignore so that you'll be protected later. It does not mean that the vaccine gave you COVID-19.

[Deep knowledge, daily. Sign up for The Conversation's newsletter.]

It all comes down to this: Some time in the coming months, you will be given a simple choice to protect yourself, your loved ones and your community from a highly transmissible and deadly disease that results in long-term health consequences for a significant number of otherwise healthy people. It may cost you a few days of feeling sick.

Please choose wisely.

Matthew Woodruff, Instructor, Lowance Center for Human Immunology, Emory University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Link:
Vaccines against COVID-19 will have side effects that's a good thing - Kiowa County Press

‘Stunning advance’ on ‘protein folding’: A 50-year-old science problem solved and that could mean big things – USA TODAY

Posted on December 4, 2020 by Prof Baldwin

A breakthrough on protein folding could unlock new possibilities into disease understanding and drug discovery, among other fields.(Photo: DeepMind)

Anew discovery about "protein folding" could unlock a world of possibilities into the understanding ofeverything from diseases to drugs, researchers say.

The breakthrough that is sending ripples of excitement throughthe science and medical communities this week deals with theshapestiny proteins in our bodies essential to all life fold into.

The so-called "protein-folding problem" has puzzled scientists for five decades, and the discovery this week from the London-based artificial intelligence lab DeepMind has been heralded as a major milestone.

"This computational work represents a stunning advance on the protein-folding problem, a 50-year old grand challenge in biology," said Venki Ramakrishnan, president of the U.K.'s Royal Society. "It has occurred decades before many people in the field would have predicted. It will be exciting to see the many ways in which it will fundamentally change biological research.

'The Ultimate': Astronomers want to put a huge telescope on the moon to study the Big Bang

Proteins are essential to life, supporting practically all of its functions, according to DeepMind, which is owned by Google. They are large, complex molecules, made up of chains of amino acids, and what a protein does largely depends on its unique 3D structure.

The ability to predict protein structures accurately enables a better understanding of what they do and how they work.

This isn't your typical space rock: There's a metal asteroid out there worth $10,000 quadrillion

When proteins are translated from their DNA codes, they quickly transform from a non-functional, unfolded state into their folded, functional state. Problems in folding can lead to diseases such asAlzheimer's and Parkinson's.

The companys breakthrough essentially means that it figured out how to use artificial intelligence to deliver relatively quick answers to questions about protein structure and function that would take many months or years to solve using currently available methods, according to STAT News.

Lunar discovery: Water discovered on sunlit part of the moon for the first time, NASA says

DeepMinds program, called AlphaFold, outperformed about 100 other teams in a biennial protein-structure prediction challenge called CASP, short for Critical Assessment of Structure Prediction, according to the journal Nature.

We have been stuck on this one problem how do proteins fold up for nearly 50 years," said University of Maryland professor John Moult, co-founder and chair of CASP. "To see DeepMind produce a solution for this, having worked personally on this problem for so long and after so many stops and starts wondering if wed ever get there, is a very special moment.

Researchers from DeepMind plan to publish their results in a peer-reviewed journal in the near future.

Read or Share this story: https://www.usatoday.com/story/news/nation/2020/12/03/protein-folding-discovery-major-breakthrough-deepmind/3809693001/

New AI That Predicts Shape of Proteins Could Solve 50-Year Problem – The Great Courses Daily News

Posted on December 4, 2020 by Prof Baldwin

By Jonny Lupsha, News Writer

According to The New York Times, a lab in London may have developed an artificial intelligence that can do a years-long task in less than a day, solving a longstanding problem of biology. For biologists, identifying the precise shape of a protein often requires months, years, or even decades of experimentation, the article said. It requires skill, intelligence, and more than a little elbow grease.

Now, an artificial intelligence lab in London has built a computer system that can do the job in a few hoursperhaps even a few minutes.

The article said that the laboratory in question, DeepMind, analyzes a string of amino acids that make up a protein and then rapidly and reliably predicts its shape. But why is that so important?

The study of folding proteins began in the 1950s with American biochemist Christian Anfinsen playing a key role.

The first experiments began by taking a protein out of the cell, unfolding it, and then seeing if it could refold in a test tube, independent of any cellular factors, said Dr. Kevin Ahern, Professor of Biochemistry and Biophysics at Oregon State University. The protein Christian Anfinsen picked was the enzyme ribonuclease A, also known as RNase, which turned out to be a serendipitous choice. RNase is relatively small as proteins goabout 100 amino acidsand it is also extraordinarily stable.

Dr. Ahern said that most enzymes are very sensitive to changes in temperature or pH balance, but RNase is not. Anfinsen showed that once an enzyme is unfolded, its capable of refolding outside the cell. His work earned him the 1972 Nobel Prize for Chemistry. Dr. Ahern also said that this process is called renaturation because the protein gets returned to its native or natural state.

Humanity has been studying protein folding for over 60 years. What happens when proteins fold incorrectly? As it turns out, nothing good.

These are the so-called prion diseases, also known as transmissible spongiform encephalopathies or TSEs, Dr. Ahern said. Prion diseases affect humans and other animals. They are a group of degenerative disorders that affect the brain, creating microscopic holes that make the tissue look like a sponge.

He also said that one of the best-known prion diseases is bovine spongiform encephalopathy, also known as Mad Cow Disease. Animals that had it would exhibit behaviors that were consistent with neurological damage, and finding a common cause among them was difficult.

Stanley Prusiner at the University of California at San Francisco ultimately identified the infectious agent as a proteina proteinaceous infectious article he called a prion, Dr. Ahern said. That a protein could be infectious by itself was unheard of at the time. And [it] turned out to be a cellular protein found on the membrane of healthy cells; though its function to this day remains uncertain.

Protein misfolding causes several serious diseases and helps explain why the study of protein folding matters so much.

This article was proofread and copyedited by Angela Shoemaker, Proofreader and Copy Editor for The Great Courses Daily.

Dr. Kevin Ahern contributed to this article. Dr. Ahern is a Professor of Biochemistry and Biophysics at Oregon State University (OSU), where he also received his PhD in Biochemistry and Biophysics.

See more here:
New AI That Predicts Shape of Proteins Could Solve 50-Year Problem - The Great Courses Daily News

Lattman, Liu, Morrow and Ruhl elected AAAS fellows – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

Posted on December 4, 2020 by Prof Baldwin

Your Colleagues

UBNOW STAFF

Published November 30, 2020

Four UB professors have been elected fellows of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.

The honor is bestowed on AAAS members by their peers for their scientifically or socially distinguished efforts to advance science applications. The UB faculty members were among 489 members to receive the prestigious distinction this year.

The new UB fellows include:

AAAS fellows will be recognized in the journal Science on Nov. 27. An induction ceremony will be held during the virtual AAAS Fellows Forum on Feb. 13.

Eaton Lattman (biological sciences)

Lattman was honored for his distinguished contributions in scholarship, education and leadership in the fields of molecular biophysics and structural biology.

A prolific researcher in crystallography and biophysics, Lattman has focused on protein folding and on development and improvement of methods in protein crystallography. He has pioneered the emerging field of using X-ray free electron lasers to study biological and nonbiological processes.

Lattman spent nearly his entire academic career at Johns Hopkins University, as professor of biophysics in both the School of Medicine and the Krieger School of Arts and Sciences, where he also served as dean of research and graduate education. He played a key role in establishing the Hopkins Institute for Biophysical Research.

In 2008, Lattman came to Buffalo to serve as chief executive officer at Hauptman-Woodward Medical Research Institute. He joined the UB Department of Structural Biology in 2009.

In 2013, he was instrumental in the awarding of a $25 million U.S. National Science Foundation grant to UB and its partners to establish BioXFEL, an X-ray laser science center, to transform the field of structural biology. It was UBs first NSF Science and Technology Center Grant. Lattman was named director and led the national consortium until 2017. Under his direction, the consortium made significant progress in refining X-ray laser techniques to study biological processes and innovating new approaches to use these methods to advance materials science and other nonbiological disciplines as well. He continues to serve as a member of the BioXFEL steering committee.

Xiufeng Liu (education)

Liu was recognized for his distinguished contributions to the fields of science education research, and communicating and interpreting science to the public.

Liu is renowned for his scholarship on measuring and evaluating student achievement in science, technology, engineering and math (STEM). He served as the inaugural director of UBs Center for Educational Innovation, with a mission to improve university teaching, learning and assessment.

He also strives to increase scientific literacy among members of the public, and inspired a program at UB called Science and the Public that prepares museum curators, zoo directors, pharmacists and other informal science educators to teach science to a general audience, including by engaging in activities and debates related to science.

Liu has received more than $18 million in research funding, and published more than 100 academic articles and 10 books. He received a doctorate in science education from the University of British Columbia and a masters degree in chemical education from East China Normal University.

Janet Morrow (chemistry)

Morrow was honored for her distinguished contributions to the field of inorganic complexes and their biomedical applications, particularly for magnetic resonance imaging contrast agents and for nucleic acid modifications.

Morrow is an expert in bioinorganic chemistry, with a wide range of innovations and publications in the field. The central theme of her research is the synthesis of inorganic complexes for biomedical diagnostics, sensing or catalytic applications. Focus areas include research and development of novel MRI contrast agents, yeast cell labeling with metal complex probes to track infections, and bimodal imaging agents. Morrow is also an inventor and entrepreneur, having co-founded Ferric Contrast, a startup that is developing iron-containing MRI contrast agents.

She is a recipient of the Jacob F. Schoellkopf Medal presented by the Western New York section of the American Chemical Society, the UB Exceptional Scholar Award for Sustained Achievement, the National Science Foundation Award for Special Creativity and the Alfred P. Sloan Research Fellowship. Morrow holds a doctorate in chemistry from the University of North Carolina at Chapel Hill and a bachelors degree in chemistry from the University of California, Santa Barbara.

Stefan Ruhl (dentistry and oral health sciences)

Ruhl was recognized for his distinguished contributions to the field of oral biology, particularly for work on glycan-mediated microbial adhesion in the oral cavity.

Ruhl is an internationally renowned expert on saliva, oral bacteria and the oral microbiome. His research attempts to unravel the roles that saliva and microorganisms play in health, including in adhesion to the teeth and surfaces of the mouth, defense against pathogens and colonization of the oral cavity. He investigates the molecular mechanisms of microbial binding to glycans, a common but little understood class of biomolecules that help bacteria attach to host surfaces, including those in the mouth. The goal of his lab is to harness tools that ultimately help scientists examine how the microorganisms bind to glycans in the mouth to form dental biofilms more commonly known as plaque increasing the risk for cavities and periodontal disease.

He was among the first researchers to catalogue the human salivary proteome, which is the entirety of proteins present in saliva and in salivary gland ductal secretions. Ruhl has led or participated in recent studies that have identified how saliva is made, tracing each salivary protein back to its source. He also discovered that 2 million years of eating meat and cooked food has led humans to develop a saliva that is now starkly different from that of chimpanzees and gorillas, our closest genetic relatives. This seminal discovery has resulted in collaborative projects exploring saliva to understand the factors that helped shape human evolution and, in particular, the evolution of the human mouth. These evolutionary projects identified a starch-digesting enzyme called amylase in the saliva of dogs and various other starch-consuming mammals, and through analysis of a salivary mucin protein found genetic evidence that humans may have mated with a ghost species of archaic humans.

Ruhl received the 2020 Distinguished Scientist Award in Salivary Research and the 2014 Salivary Researcher of the Year award from the International Association for Dental Research, as well as the UB Exceptional Scholar Award for Sustained Achievement. He holds a doctor of dental surgery degree and a doctoral degree in immunology from Georg-August University of Gttingen.

Here is the original post:
Lattman, Liu, Morrow and Ruhl elected AAAS fellows - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) – The Media Line

Posted on December 4, 2020 by Prof Baldwin

Tel Aviv University researchers use tiny molecular scissors to target aggressive metastatic cancer cells

Israeli scientists have developed a cutting-edge nanotechnology system that can destroy cancerous cells in mice.

The Tel Aviv University team of researchers pioneered a treatment method that is so precise, it is almost as if tiny molecular scissors were being used to kill the cancer.

We developed a delivery system for these molecular scissors that can specifically reach tumor cells while leaving normal cells intact, Dr. Daniel Rosenblum, a postdoctoral fellow from the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University, told The Media Line.

By cutting their DNA in specific genes that are responsible for cell division or cell survival, we basically neutralize them and they die from the treatment, he said. The system we developed is based on the Cas9 CRISPR protein in a [messenger] RNA format.

The process, known as CRISPR genome editing, allows researchers to alter DNA sequences. Specifically, scientists at the university created what is known as CRISPR-LNPs, a lipid nanoparticle delivery system that carries a genetic messenger (known as messenger RNA), along with a navigation system that can recognize cancerous cells.

The findings of the peer-reviewed research were published last month in the Science Advances journal.

This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer in a living animal effectively,said Prof. Dan Peer, vice president for Research and Development at Tel Aviv University and head of TAUs Laboratory of Precision NanoMedicine.

The idea there is to take the cells from the patients, edit them in a plate outside the body and then inject them back into the patient, he told The Media Line. We believe that this could be expanded to much more than just the two models that we have tried.

So far, researchers at Tel Aviv University have tested the technology on mice and have observed no adverse reactions. This stands in contrast to chemotherapy, which kills both cancerous and healthy cells.

The CRISPR-LNPs were tested on glioblastoma tumors, an extremely aggressive type of brain cancer that has a five-year survival rate of only 3%. In addition, the researchers tested the system on metastatic ovarian cancer, a major cause of death among women and the most lethal cancer in the female reproductive system.

Wake up to the Trusted Mideast News source Mideast Daily News Email

For the glioblastoma tumors, the treatment was found to double the average life expectancy of mice and improve their overall survival rate by about 30%. For ovarian cancer, the overall survival rate rose by a whopping 80%.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried

We envision that we can simply inject [the treatment] into the body and because of the GPS they can find their way to the tumor, Anna Gutkin, a doctoral student in the laboratory, told The Media Line. We encountered several hurdles in the development of this technology but its exciting to work on this. It really opens new avenues for us to develop novel therapies.

Aside from its potentially revolutionary impact on future cancer treatments, the technology also opens the door for treating rare genetic diseases and viral diseases such as AIDS, according to the researchers. A similar technology based on messenger RNA currently is being used by Pfizer (BioNTech) and Moderna for their COVID-19 vaccines.

Our system is a bit more sophisticated both from the materials they are created from [and] we also gave it a GPS system, which is pretty unique, Rosenblum noted.

In the future, Peer and his team hope to test the groundbreaking technology on larger animal models. Human trials are expected to begin in about two years.

Because of the coronavirus crisis we have witnessed how fast new approaches could be translated into the clinic, Peer said.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried, he concluded.

The rest is here:
Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) - The Media Line

Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 – The Haitian-Caribbean News Network

Posted on December 4, 2020 by Prof Baldwin

Nanomedicine Market Forecast 2020-2026

The Global Nanomedicine Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Nanomedicine Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/11972

The Report Covers the Following Companies:CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

By Types:Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

By Applications:Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/11972

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Nanomedicine Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/11972

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

The rest is here:
Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 - The Haitian-Caribbean News Network

Futurist Transhuman News Blog

Author Archives: Prof Baldwin

Taking ‘Achija’, the legacy of Indian fast-food to Toronto and New York – NewsPatrolling

I Went a Year Without Meat. Here’s What I Learned. – InsideHook

Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 – PharmiWeb.com

Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing – Business Wire

Is the great stagnation over? – The Week

BioAge Raises $90M to Treat Aging and Age-related Diseases – GlobeNewswire

Tigerlily Foundation to Lead Historic Special Session on Health Equity, Collaboration and Partnership at the 2020 San Antonio Breast Cancer Virtual…

Ciara and ex-Lululemon CEO launch new clothing brand with ‘more to it than fashion’ – CNBC

Re-Inventing the Wheel: How CEOs Are Driving the Sustainable Tire of the Future – Triple Pundit

What is the secret to aging well? – MarketWatch

NUS-led team uncovers molecule that promotes muscle health when magnetised – Newswise

Lifetime perspective on alcohol and brain health – The BMJ

Stem Cell Market Analysis By Industry Value, Market Size, Top Companies And Growth Forecast To 2027 – Cheshire Media

Go with the Flowbee: George Clooney reveals how he cuts his hair – The Guardian

Vaccines against COVID-19 will have side effects that’s a good thing – Kiowa County Press

‘Stunning advance’ on ‘protein folding’: A 50-year-old science problem solved and that could mean big things – USA TODAY

New AI That Predicts Shape of Proteins Could Solve 50-Year Problem – The Great Courses Daily News

Lattman, Liu, Morrow and Ruhl elected AAAS fellows – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) – The Media Line

Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 – The Haitian-Caribbean News Network